In the rotavirus SAll surface protein VP4, the trypsin cleavage sites associated with the enhancement of infectivity are flanked by two amino acid regions that are highly conserved among different rotaviruses. We have tested the ability of synthetic peptides that mimic these two regions to induce and prime for a rotavirus neutralizing antibody response in mice. After the peptide immunization schedule, both peptides induced peptide antibodies, but neither was able to induce virus antibodies, as measured by an enzyme-linked immunosorbent assay or a neutralization assay. However, when the peptide-inoculated mice were subsequently injected with intact SAll virus, a rapid and high neutralizing antibody response was observed in mice that had previously received the peptide comprising amino acids 220 to 233 of the VP4 protein. This neutralizing activity was serotype specific; however, this peptide was also able to efficiently prime the immune system of mice for a neutralizing antibody response to the heterotypic rotavirus ST3 when the ST3 virus was used for the secondary inoculation.
In the rotavirus SAll surface protein VP4, the trypsin cleavage sites associated with the enhancement of infectivity are flanked by two amino acid regions that are highly conserved among different rotaviruses. We have tested the ability of synthetic peptides that mimic these two regions to induce and prime for a rotavirus neutralizing antibody response in mice. After the peptide immunization schedule, both peptides induced peptide antibodies, but neither was able to induce virus antibodies, as measured by an enzyme-linked immunosorbent assay or a neutralization assay. However, when the peptide-inoculated mice were subsequently injected with intact SAll virus, a rapid and high neutralizing antibody response was observed in mice that had previously received the peptide comprising amino acids 220 to 233 of the VP4 protein. This neutralizing activity was serotype specific; however, this peptide was also able to efficiently prime the immune system of mice for a neutralizing antibody response to the heterotypic rotavirus ST3 when the ST3 virus was used for the secondary inoculation.
Rotaviruses, the single most important cause of acute viral gastroenteritis in the young of a number of mammalian and avian species, including humans (19) , are comprised of two capsid layers that contain the viral genome composed of 11 segments of double-stranded RNA (31) . The outer capsid is formed by two polypeptides (12) , VP4 (formerly called VP3) and VP7, which are encoded in simian rotavirus SAll by genome segments 4 and 9, respectively (2, 6, 22, 25) .
VP7, a 37-kilodalton glycoprotein (3, 11) , induces neutralizing antibodies that specify the viral serotype (5, 17) and is thought to be involved in the attachment of the virus to the host cell (26, 32) . VP4, the other surface polypeptide of rotaviruses, is an 88-kilodalton protein (12, 13) that has been identified as the virus hemagglutinin (20) and has been associated with the determination of virulence in vivo (29) . Antibodies directed at this protein neutralize the viral infectivity in vitro (30, 37) and passively protect mice against heterologous rotavirus challenge in vivo (30) .
The infectivity of rotaviruses in cell culture can be increased by, and probably is dependent on, trypsin treatment (8, 13, 27) . This proteolytic activation of the virus produces at least two specific cleavages on VP4 at amino acids 241 and 247 (22) , generating two cleavage products, VP5 (60 kilodaltons) and VP8 (28 kilodaltons). These specific cleavages probably mediate penetration of the virion into the cell (14) .
Functional and topographical analyses of epitopes on the VP4 polypeptide of simian and human rotaviruses have been carried out (7, 33, 36 (24, 35) . It (12) . Essentially, after Freon extraction and polyethylene glycol precipitation of the infected cell lysates, the virions were separated by centrifugation in a linear sucrose gradient.
Choice and synthesis of peptides. The VP4 protein-derived peptides represented amino acid regions 220 through 233 (peptide VP4-1) and 258 through 271 (peptide VP4-2). These regions, which flank the trypsin cleavage sites associated with the enhancement of rotavirus infectivity, are highly conserved among different rotaviruses. As a negative control, we used peptide VP7-1, which comprises amino acids 211 through 223 of the SAil VP7 protein and has been shown by others not to induce neutralizing antibodies (18) .
Solid-phase peptide synthesis was conducted by the Barany and Merrifield method (4) with a 1% cross-linked divinylbenzene resin esterified to the appropriate t-butoxycarbonyl amino acid and suitably protected t-butoxycarbonyl amino acids from Peninsula Laboratories (22 acid analysis of the resulting products on a Durrum D-500 amino acid analyzer confirmed that all three peptides had the predicted composition.
Coupling of the peptides to BSA. The peptides were coupled to bovine serum albumin (BSA; Pentax) as follows. BSA (40 mg) was added to 5 mg of peptide in 2.5 ml of twice-distilled water. Then 250 mg of 3-3-dimethylcarbodiimide in 1.5 ml of water was added dropwise, and the mixture was stirred for 6 h at 30°C and kept at -20°C until use.
Cross-linking of peptides with glutaraldehyde. A solution of glutaraldehyde was added dropwise to 4 mg of peptide in 1 ml of phosphate buffer (0.1 M, pH 7.6) until a final concentration of 0.25% was reached. This mixture was stirred for 4 h at room temperature, and then glycinamide was added to 0.025 M. After further stirring for 30 min, the aggregated peptides were kept at -20°C until use.
Immunization schedule. Male BALB/c mice 7 to 9 weeks of age were screened on day 0 for neutralizing antibodies to SA1l rotavirus as described below. Those mice whose preimmune sera at dilutions of 1:50 failed to neutralize SAil were divided into groups of five and were immunized each with 100 ,ug of the corresponding peptide, cross-linked with glutaraldehyde. All mice were injected subcutaneously with 200 ,ud of an emulsion of the respective antigen and adjuvant. Freund complete adjuvant was used for the first immunization; for subsequent injections, incomplete adjuvant was used. Mice in the control groups (which did not receive peptide) were injected with an emulsion of saline solution and the corresponding adjuvant. The mice in the various groups received seven injections on weeks 0, 2, 4, 6, 8, 10, and 12. Mice were bled on weeks 0, 3, 5, 7, 9, 11, and 13. On week 14, 15 days after the last peptide or mock administration, a single dose of the corresponding purified rotavirus strain (50 ,ug) was given subcutaneously and intramuscularly, and the mice were bled every week during the next 4 to 5 weeks. All collected sera were heat inactivated at 56°C for 1 h and stored at -20°C.
Neutralizing antibody assay. Neutralizing antibody titers in mouse sera were measured by an immunochemical focus reduction neutralization test (1 (Fig. 1B) . However, these antibodies did not react with the virus in an ELISA and did not have neutralizing activity against the SAl virus ( Fig. 1A and C) . It has been reported that selected synthetic peptides of poliovirus, despite the fact that they do not induce neutralizing antibodies by themselves, are able to efficiently and specifically prime the immune systems of rabbits for an enhanced neutralizing antibody response after a subsequent inoculation of intact virus (10) . On the other hand, it has been shown that synthetic peptides containing only T-helper cell determinants are able to prime the immune response of animals for an enhanced antibody response to several epitopes of the microorganism (15, 28) .
To determine whether the synthetic rotavirus peptides were capable of priming a neutralizing antibody response to SAl virus, the mice in all four groups were inoculated with 50 ,ug of purified SAl particles after the peptide immunization schedule had been completed. At 2 weeks after inoculation with the SAl virions, the virus particle and neutralizing antibody responses of mice in the groups that had previously received peptides VP4-2 and VP7-1 were comparable with the response observed in the control group (which had not been immunized with peptides), whereas the response in the group that initially received peptide VP4-1 was at least 4 and 20 times higher for virus particle and neutralizing antibodies than the control group, respectively (Fig. 1) . Interestingly, the titer of peptide antibodies in the VP4-2 and VP7-1 groups did not increase significantly after immunization with the SAl particles, whereas the peptide VP4-1 antibody titer had a threefold increase. This observation is compatible with the fact that anti-SAl virus hyperimmune sera did not recognize any of the peptides in an ELISA (data not shown), suggesting that the peptide VP4-1 antibody response observed after inoculation with the virus is the result of specific stimulation of peptide-induced memory B cells by the virus particles.
Specificity of the secondary response. Since the amino acid region represented in peptide VP4-1 was selected for being highly conserved among rotavirus strains belonging to different serotypes, we tested selected sera from mice of the group that had received peptide VP4-1 and had been reinoculated with the virus particles for the ability to neutralize rotaviruses of different serotypes. The sera analyzed had no neutralizing activity against the human rotaviruses Wa (serotype 1) and S2 (serotype 2), whereas they had a low but significant neutralization titer against human rotavirus ST3, which belongs to serotype 4 (Table 1) .
Heterotypic priming with peptide VP4-1. The secondary, serotype-specific neutralizing antibody response observed after inoculation of the SAl particles in mice that had previously received peptide VP4-1 did not necessarily imply that this peptide would not be able to prime an antibody response to viruses of serotypes different from SAll. Therefore, we tested this possibility by immunizing three groups of five mice with peptide VP4-1. Three control groups were inoculated with adjuvant alone. At the end of the peptide immunization schedule, one group that had received the peptide and one control group were inoculated with 50 ,ug of either Wa, S2, or ST3 purified rotavirus strains, and neutralizing antibodies to the corresponding inoculated rotavirus strain were determined during the 5 following weeks. The neutralizing antibody response to Wa and S2 rotaviruses was not influenced by the previous administration of peptide (Fig. 2) . However, the neutralizing antibody titers to rotavirus ST3 were much higher in the mice that had been immunized with peptide VP4-1 than in the control mice that did not receive the peptide, indicating that the SAil-derived synthetic peptide was able to prime a neutralizing immune response to rotavirus ST3. Again, the secondary antibody response was highly specific for the strain used for reinoculation, with only a low neutralization activity against rotavirus SAll (Table 1) .
DISCUSSION
In this work we present evidence that the region between amino acids 220 and 233 is able to prime for a neutralizing antibody immune response to SAil and ST3 rotavirus strains. This region is highly conserved among different rotaviruses and is very close to the trypsin cleavage sites identified by L6pez et al. (22) at amino acid positions 241 and 247.
Recently, Streckert et al. (34) reported that a synthetic peptide (amino acids 228 to 241) corresponding to the cleavage region of the rotavirus SAil VP4 protein was able to induce neutralizing antibodies. The sequence contained in that peptide overlaps by six amino acids the sequence of peptide VP4-1 (amino acids 220 to 233) described in this work. Since in our hands peptides containing amino acids 231 to 241 and 231 to 247 of the SAll VP4 protein were unable to induce neutralizing antibodies by themselves or to prime the immune system of mice, it is tempting to suggest that the overlapping region between the two peptides (amino acids 228 to 233) might be responsible for the observed priming effect.
It is interesting to note that amino acid 231 in the SAll VP4 protein is an arginine (22) , which is absolutely conserved in all sequenced VP4 proteins from different rotavirus strains (16, 21, 23, 24) and which represents a potential trypsin cleavage site that would have not been identified by the NH2-terminal sequence analysis of the VP4 trypsin cleavage products carried out by L6pez et al. (22) , since cleavage at positions 241 and 247 would have removed the potential NH2 terminus generated by cleavage at arginine 231. If this were the case, the peptide VP4-1 would very closely resemble the newly generated carboxy terminus after trypsin activation of the virus.
Escape mutations to neutralization by VP4-specific neutralizing monoclonal antibodies have been recently mapped to three and six different regions in human and rhesus rotaviruses, respectively (24, 35) . The three neutralization domains identified in human rotaviruses were located to VP5, the carboxy-terminal trypsin cleavage product of VP4, whereas five of the six neutralization domains of rhesus rotavirus were located to VP8, the NH2-terminal trypsin cleavage product. As a result, only one neutralization domain seems to be shared (around amino acids 392 and 393) by the two sets of neutralizing antibodies used for the selection of the analyzed escape mutants. It is interesting that none of the escape mutations was mapped in or near the two trypsin cleavage sites associated with the enhancement of rotavirus infectivity. These results would suggest that the neutralizing antigenic determinants in the trypsin cleavage region (like the one reported by Streckert et al. [34] ) are less immunopotent than other regions of VP4. However, the absence of escape mutations in this region of the VP4 protein of rhesus and human rotaviruses could also be explained if either of the neutralization epitopes contained within this region was only present in some rotavirus strains. This kind of strain-specific epitope has been described in poliovirus, for which there is a serotype 1-specific epitope that is not present in the other poliovirus serotypes (10) .
The enhanced neutralizing antibody response observed after immunization with SAll virus of mice that had previously received peptide VP4-1 was shown to be specific for SAll, although a minor cross-neutralization was observed with ST3 virus. However, this peptide was able to prime the mice immune system very efficiently for an ST3-specific neutralizing antibody response when the secondary inoculation was done with the ST3 virus. An analogous finding was reported by Emini et al. (9) , who showed that poliovirusspecific synthetic peptides were able to prime for hepatitis A neutralizing antibody upon exposure of primed rabbits to hepatitis A virus. However, the low neutralizing activity against poliovirus, induced directly by the peptides, was not increased upon inoculation with the hepatitis A virus.
The serotype-specific priming for rotavirus neutralizing antibody could be explained if we consider that the viral epitope(s) responsible for the priming could be present in slightly different conformations in ST3 and SAll viruses. When we compared the sequences of the region at amino acids 220 through 233 among the virus strains used in this work (Fig. 3) , it was interesting to note that the ST3 virus has two amino acid changes as compared with the SAl1 virus, whereas the Wa strain, which was not primed by the peptide, has only one amino acid change. The sequence of S2 virus has not been reported, but the sequence of DS1, which is also a serotype 2 virus, has also only one change with respect to the SAl1 sequence. It is of note that the single amino acid change between either Wa or DS1 and SAl1 is in position 233, whereas the amino acids that differ between SAl1 and ST3 are at positions 222 and 227, with the sequence between amino acids 228 to 233 being identical between the two strains. This observation is consistent with the idea that the region at amino acids 228 through 233 might be responsible for the priming effect observed. However, this does not rule out the possibility that some other region of the peptide, comprising the amino acid differences mentioned, could be the responsible for the priming of neutralizing antibodies to ST3 and SAll, since the amino acid 388 of VP4, whose change allows the rhesus rotavirus variant M2 to escape from neutralization by monoclonal antibody M2, is different in rotavirus Wa, which is also neutralized by monoclonal antibody M2 (24) . On the other hand, the region within the peptide that primes for SAl1 and ST3 neutralizing antibodies might be different.
The fact that the inoculation of SAl1 virus into animals primed with peptide VP4-1 caused an increase in the peptide antibody titer, as determined by the ELISA, is suggestive that at least one B-cell epitope is shared by VP4, as it is in the virion, and peptide VP4-1. In addition, the observation that peptide VP4-1 was able to prime for a neutralizing immune response in the absence of a carrier protein indicates that this peptide can initiate its own T-helper cell response and suggests that it contains, in addition to a B-cell epitope(s), a T-cell determinant.
Several investigators (15, 28) have described a priming effect mediated by a T-helper cell epitope that was present in the same protein or another protein of the same microorganism. Therefore, the mechanism through which peptide VP4-1 is able to prime for a neutralizing antibody immune response to rotaviruses SAl and ST3 remains an open question, and further experiments should be performed before the responsibility for the priming effect can be assigned to a B-or T-cell epitope.
